However, the BRAF V600E mutation is present in approximately 10% of CRC tumors and exhibits unsuppressed cell proliferation, reduced apoptosis, and resistance to BRAF-targeted inhibitors [28]. This evidence concerns the gene BRAF and colorectal carcinoma.